Klinički tok karcinoma jajnika u zavisnosti od patohistoloških i imunohistohemijskih karakteristika tumora
Clinical course of ovarian carcinoma depending on patohistological and immunohistochemical characteristics
Author
Conić, IrenaMentor
Stanojević, ZoricaCommittee members
Vrbić, SvetislavJanković-Veličković, Ljubinka

Jovanović, Darjana
Krstić, Miljan

Metadata
Show full item recordAbstract
Introduction: According to the frequency of malignant tumours in the world, ovarian
carcinoma takes the eighth place; it is also the fifth most frequent tumour in women and the
fourth cause of cancer death in women. In early discovering and treatment of ovarian
carcinoma, before it expends out of the primary localisation, the five-year relative survival
rate is 92%. Unfortunately, only 15% of all ovarian carcinomas are discovered in the early
stage. It has been noticed that the survival rate is higher in women under the age of 65 than in
the older ones and it varies depending on the morphological type of ovarian carcinoma,
patient’s over-all health condition and the stage of the disease diffusion at the time of setting
the diagnosis. The exact cause of ovarian carcinoma occurrence is still unknown, but many
risk factors are related to the occurrence of this malignoma.
The aim of this research was to analyze the clinical and pathological characteristics of
ovarian carcinoma, as well as... to determine Nanog, Sox2, Oct3/4, Sox4, CD44. CD117, Ezh2
and Stat3 expressions in paraffin sections of ovarian carcinoma and to compare the Nanog,
Sox2, Oct3/4, Sox4, CD44, Ezh2 and Stat3 expressions with the clinical and pathological
characteristics of ovarian carcinoma.
Methods: During the research, the immunohistochemical method was applied.
Paraffin sections of the tissue of ovarian carcinoma 5μm thick were used.
Conclusion: Unfavourable clinical course of ovarian carcinoma was related to the
positive Nanog, Sox2 and Oct3/4 expression, as well as with the absence or low expression of
Sox4, CD117 and CD44, while the loss of Ezh2 and Stat3 expressions in ovarian carcinoma,
indicated significantly longer survival.